Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

The efficacy and safety of switching to olverembatinib or continuing original TKI therapy in CML-CP patients treated with at least two prior TKIs: A prospective, multicenter, controll trial

Bingbing Wen, Junchong Peng, Bingcheng Liu et al. Nov 03, 2025 pp. 3779-3779 10.1182/blood-2025-3779

Abstract Introduction: Olverembatinib (HQP1351) is a novel third-generation BCR-ABL1 tyrosine kinase inhibitor (TKI) in chronic myeloid leuke...

Efficacy of cyclosporine and antithymocyte or antilymphocyte globulin in the management of aplastic anemia: A systematic review and meta-analysis

Stephin Saji, Ajay Kumar, Ramsha Manzoor et al. Nov 03, 2025 pp. 6442-6442 10.1182/blood-2025-6442

Abstract Introduction: The efficacy of combined cyclosporine (CsA) and antithymocyte/antilymphocyte globulin (ATG/ALG) therapy for aplastic...

Therapeutic potential of mitochondrial transplantation in the treatment of MDS

Takeshi Fujino, Tina Napso, Gat Pozner et al. Nov 03, 2025 pp. 231-231 10.1182/blood-2025-231

Abstract Currently the only curative treatment option for patients with myelodysplastic syndromes (MDS) is allogeneic bone marrow transplant...

Germline mediated HR deficiency, alu element duplication, and immune pathway alterations define aggressive, drug-resistant multiple myeloma

Anindyajit Banerjee, Sombuddharoy Bhowmick, Smreti Vasudevan et al. Nov 03, 2025 pp. 7461-7461 10.1182/blood-2025-7461

Abstract Background: Multiple Myeloma (MM) is a plasma cell malignancy characterized by genomic instability, often manifesting as chromothri...

Ziftomenib in combination with venetoclax and azacitidine in relapsed/refractory NPM1-m or KMT2A-r acute myeloid leukemia: Updated phase 1a/b safety and clinical activity results from KOMET-007

Ghayas Issa, Amir Fathi, Amer Zeidan et al. Nov 03, 2025 pp. 764-764 10.1182/blood-2025-764

Abstract Introduction: Leukemogenesis is driven by nucleophosmin 1 mutations(NPM1-m) or lysine methyltransferase 2A rearrangements(KMT2A-r)...

Quality initiative in first-line multiple myeloma assessing the use of anti-CD38 agents and quadruplet therapy

Joseph Franz, Dhaval Mehta, Kathleen Dorritie et al. Nov 03, 2025 pp. 8120-8120 10.1182/blood-2025-8120

Abstract Background: The University of Pittsburgh Medical Center (UPMC) partnered with IntegraConnect to conduct a quality initiative (QI) s...

Barriers to optimal care and educational opportunities for european physicians treating patients with relapsed/refractory (R/R) CLL

Ryan Topping, Alexandra Howson, Timothy Quill et al. Nov 03, 2025 pp. 2875-2875 10.1182/blood-2025-2875

Abstract Background: Healthcare professionals (HCPs) who manage patients with CLL are challenged to provide optimal care as treatment paradi...

Digital diagnosis:  the development of electronic laboratory simulations to promote active learning in hematology among first-year medical students

Raymond Pastore, Amy Chadburn Nov 03, 2025 pp. 6425-6425 10.1182/blood-2025-6425

Abstract BACKGROUND Hematology inundates learners with facts and details. Teaching students to identify patterns and render diagnoses poses s...

Addressing institutional barriers in sickle cell pain management: A resident-led quality improvement study

Dhara Popat, Siddhant Jain, Poornima Ramadas Nov 03, 2025 pp. 6155-6155 10.1182/blood-2025-6155

Abstract INTRODUCTION Sickle Cell Disease (SCD) affects over 100,000 individuals in the U.S., with vaso-occlusive crises (VOC) being the lead...

Active cancer as a risk factor for inappropriate VTE prophylaxis: Data from a single center study

Devang Namjoshi, Akshat Saxena, Panah Parab et al. Nov 03, 2025 pp. 6680-6680 10.1182/blood-2025-6680

Abstract Introduction: Hospitalized patients with cancer represent a high-risk group for venous thromboembolism (VTE) due to a hypercoagulab...

Outcomes of autologous transplant (ASCT) in patients with chemosensitive late relapse of large B-cell lymphoma (LBCL)

Lorenzo Iovino, Ningxin Ma, Mohamed Kharfan-Dabaja et al. Nov 03, 2025 pp. 5483-5483 10.1182/blood-2025-5483

Abstract Introduction CAR T cell treatment is the standard of care for patients (pts) with primary refractory and relaps...

Secondary Acute Myeloid Leukemia transformed from chronic myelomonocytic leukemia is strongly resistant to venetoclax but demonstrates sensitivity to anti-GM-CSF lenzilumab immunotherapy

Kelly Lim, Monika Kutyna, Akash Kalro et al. Nov 03, 2025 pp. 1714-1714 10.1182/blood-2025-1714

Abstract Introduction:Secondary acute myeloid leukemia arising from prior myelodysplastic syndrome or chronic myelomonocytic leukemia accoun...

Selecting the optimal bridging therapy for B-ALL: A multicenter comparison of blinatumomab, inotuzumab ozogamicin, and CAR-T prior to allo-HSCT

Ao-Ran Zhang, Guanhua Hu, Xianying Yin et al. Nov 03, 2025 pp. 4298-4298 10.1182/blood-2025-4298

Abstract Background: The incorporation of novel immunotherapeutic and cellular approaches—including blinatumomab, inotuzumab ozogamicin, and...

Belumosudil for chronic graft-versus-host disease in children under 12: A retrospective analysis of effectiveness and safety

Jingtao Chen, Jianyun Liao, Fen Huang et al. Nov 03, 2025 pp. 2467-2467 10.1182/blood-2025-2467

Abstract Background: Chronic graft-versus-host disease (cGVHD) is a major cause of morbidity and mortality following allogeneic hematopoieti...

EZH2 gain-of-function events distinctly impact germinal center B cells depending on timing in the B lineage

Sofia Smith, George Souroullas Nov 03, 2025 pp. 3261-3261 10.1182/blood-2025-3261

Abstract The two most common types of Non-Hodgkin Lymphoma (NHL) are Diffuse Large B Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL). Up...

Spatial profiling of the bone marrow microenvironment in patients with IgM gammopathies reveals a T cell–Enriched tumor niche associated with asymptomatic waldenstrom macroglobulinemia progression

David Cordas Dos Santos, Kane Foster, Daniel Heilpern-Mallory et al. Nov 03, 2025 pp. 3559-3559 10.1182/blood-2025-3559

Abstract INTRODUCTION While the genetic drivers of Waldenström macroglobulinemia (WM) are well characterized, the contribution of the bone ma...

Feasibility, reliability, and accuracy of point-of-care measurements of fetal hemoglobin

Charles Quinn, Abigail Kincaid, Kathryn McElhinney et al. Nov 03, 2025 pp. 4739-4739 10.1182/blood-2025-4739

Abstract Background: Fetal hemoglobin (HbF) is a key determinant of disease severity and an important therapeutic biomarker in sickle cell d...

Management and outcomes of patients diagnosed with chronic myeloid leukemia in blast Phase: A multicenter analysis by the h jean khoury cure CML consortium

Akriti Jain, Umar Iqbal, Colin Vale et al. Nov 03, 2025 pp. 904-904 10.1182/blood-2025-904

Abstract Introduction: Despite advent of multiple tyrosine kinase inhibitors (TKIs) and newer treatment methods for AML...

Efficacy and safety of melphalan/TBI-based conditioning regimens (MCAC/TCAC) for autologous HSCT in adult acute lymphoblastic leukemia: A multicenter, prospective cohort study

Xinhui Zheng, Jieya Luo, Xin Chen et al. Nov 03, 2025 pp. 3347-3347 10.1182/blood-2025-3347

Abstract Introduction Autologous hematopoietic stem cell transplantation (auto-HSCT) is a primary consolidation option f...

Patterns of palliative care utilization across health sectors in patients with aggressive non-Hodgkin lymphoma.

Joanne Britto, Ana Gayowsky, Hira Mian et al. Nov 03, 2025 pp. 6268-6268 10.1182/blood-2025-6268

Abstract Introduction: Patients with aggressive non-Hodgkin lymphoma (NHL) experience high physical and psychological burden related to thei...

Bridging the rural gap: Real-world teclistamab outcomes from the u.S. midwest myeloma network

Adam Stepanovic, Charles Pai, Arun Augustine et al. Nov 03, 2025 pp. 4597-4597 10.1182/blood-2025-4597

Abstract Background: Teclistamab, a BCMA×CD3 bispecific T-cell engager, offers an off-the-shelf immunotherapy option for relapsed/refractory...

FLT3 testing and guideline concordance in Acute Myeloid Leukemia across an Indiana health system

Logan Van Ravenswaay, David Reeves, Sarah Nisly Nov 03, 2025 pp. 7955-7955 10.1182/blood-2025-7955

Abstract Background: FLT3 mutations occur in approximately 30% of patients with acute myeloid leukemia (AML) and are ass...

Sinusoidal endothelial cell-derived FGF23 modulates hematopoiesis in mice

Jackie Fretz, Sydney Phillips, Allison Fisher et al. Nov 03, 2025 pp. 524-524 10.1182/blood-2025-524

Abstract Fibroblast growth factor 23 (FGF23), a phosphaturic hormone produced by osteocytes, has been found to negatively regulate erythropo...

Therapeutic effects of Tmprss6 suppression are negated by iron overload in a mouse model of beta-thalassemia

Vida Zhang, Terry Barrett, Elizabeta Nemeth et al. Nov 03, 2025 pp. 526-526 10.1182/blood-2025-526

Abstract Beta-thalassemia, caused by genetic deficiency of beta-globin, is characterized by ineffective erythropoiesis and anemia. In additi...

Symptom burden in patients with cancer and thromboembolism: A population-based matched cohort study

Deborah Siegal, Zoe O'Neill, Lena Nguyen et al. Nov 03, 2025 pp. 704-704 10.1182/blood-2025-704

Abstract Background: Arterial (ATE) and venous thromboembolism (VTE) are common complications of cancer, but their impact on cancer symptom...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page